Federal Agency for Medicines and Health Products (FAMHP) (FAMHP)
Federal Agency for Medicines and Health Products (FAMHP) is the official source of medicine shortage information for Belgium (Europe). Mederti checks its register daily and links every notice back to the original publication.
- Official register
- pharmastatus.be
- Country
- Belgium
- Notices tracked by Mederti
- 1,985
- Last checked
- 1 Nov 2026
Latest notices from FAMHP
- Diltiazem Hydrochloride — anticipated, medium, since 12 Nov 2026 (source)
- Timolol; Travoprost — anticipated, medium, since 11 Nov 2026 (source)
- Amisulpride — anticipated, medium, since 6 Nov 2026 (source)
- Somatropin — anticipated, medium, since 6 Nov 2026 (source)
- Olmesartan Medoxomil; Amlodipine — anticipated, medium, since 5 Nov 2026 (source)
- Olmesartan Medoxomil — anticipated, medium, since 5 Nov 2026 (source)
- Tetracaine — anticipated, medium, since 4 Nov 2026 (source)
- Medroxyprogesterone Acetate — anticipated, medium, since 2 Nov 2026 (source)
- Colistimethate Sodium — anticipated, high, since 2 Nov 2026 (source)
- Escina — active, medium, since 30 Oct 2026 (source)
- Etoricoxib — active, medium, since 29 Oct 2026 (source)
- Perflutren — active, medium, since 29 Oct 2026 (source)
- Gabapentin — active, medium, since 29 Oct 2026 (source)
- Montelukast — active, medium, since 29 Oct 2026 (source)
- Tamsulosin Hydrochloride — active, medium, since 29 Oct 2026 (source)
Every FAMHP notice, searchable and alertable
Search Belgium's full register alongside 50+ other countries — free for individual pharmacists and clinicians.
Create a free accountMederti is not affiliated with or endorsed by Federal Agency for Medicines and Health Products (FAMHP). All notices remain the property of their publisher and are linked to the original source.